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Cardiometabolic syndrome (CMS) describes the cluster of metabolic and cardiovascular dis-
eases that are generally characterized by impaired glucose tolerance, intra-abdominal adi-
posity, dyslipidemia, and hypertension. CMS currently affects more than 25% of the world’s
population and the rates of diseases are rapidly rising. These CMS conditions represent crit-
ical risk factors for cardiovascular diseases including atherosclerosis, heart failure, myocar-
dial infarction, and peripheral artery disease (PAD). Therefore, it is imperative to elucidate
the underlying signaling involved in disease onset and progression. The c-Jun N-terminal
Kinases (JNKs) are a family of stress signaling kinases that have been recently indicated in
CMS. The purpose of this review is to examine the in vivo implications of JNK as a poten-
tial therapeutic target for CMS. As the constellation of diseases associated with CMS are
complex and involve multiple tissues and environmental triggers, carefully examining what
is known about the JNK pathway will be important for specificity in treatment strategies.
Introduction
The World Health Organization and the American Society of Endocrinology defines the term car-
diometabolic syndrome (CMS) as a combination of different dysfunctions in our body which includes
obesity, insulin resistance, dyslipidemia, and hypertension [1]. Approximately 25% of the world’s adults
currently suffer from cardiometabolic dysfunction, and this number is rapidly expanding. With this in
mind, it is paramount to uncover the underlying mechanism between these metabolic perturbations with
the potential for targeted therapy inmind. The c-JunN-terminal Kinase (JNK) pathway has been shown to
be involved in cardiometabolic factors which include inflammation, insulin resistance, immune cell differ-
entiation, and polarization. This review sets the stage for interrogation of the JNKs as possible therapeutic
targets for cardiometabolic diseases, and to propose potential explanations for the discrepant phenotypes
reported in experimental cardiovascular models.
JNK was first discovered as a microtubule-associated protein kinase in the early 1990s [2,3]. Three
separate genes encode the kinase, JNK1 (Mitogen Protein Kinase 8;MAPK8), JNK2 (MAPK9), and JNK3
(MAPK10), although alternative splicing can produce ten different protein sequences. There is much
functional overlap in JNK1 and JNK2 signaling, while less is known about the thirdmember, JNK3.While
there remains much overlap in canonical JNK signaling (see Figure 1), we are still learning about the
specificity in signaling among its members. In terms of expression, JNK1 and JNK2 are ubiquitously
expressed, while the third member, JNK3, is principally expressed in the brain and nerves, and to a lesser
extent, the heart, pancreatic islets, and testes. JNK3 studies have thus far largely focused on the function
of JNK3 in the nervous system, and its role in neurodegenerative diseases like Alzheimer’s [4]. Currently,
there is little knowledge about JNK3 in other tissue types.
JNK kinases can be activated by a number of external stimuli (e.g. cytokines, UV radiation, reactive
oxygen species (ROS), heat shock, shear stress, and free fatty acids (FFA)) that contribute to its diverse role
in a wide spectrum of biological processes affecting both nuclear and non-nuclear substrates [5] (Figure
1). The JNKs can directly bind and phosphorylate several transcription factors, including c-Jun, JunB,
c-fos, ATF2, NFAT etc., that serve as the main mediators of JNK biological responses [6,7]. However,
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Figure 1. JNK pathway
A schematic representation of the JNK pathway. (A) The JNK pathway can be activated by many stimuli, including UV, reactive
oxygen species (ROS), growth factors, inflammatory cytokines, and a wide spectrum of cellular stresses. These stress signals then
orchestrate the binding of multiple JNK-related proteins to scaffolding proteins (JIP1-2, POSH, Arrestin2-3). Upstream kinases
phosphorylate and activate JNK which then phosphorylates different downstream targets, including protein kinases, cytosolic
substrates, and transcription factors, leading to biological responses. (B) The JNK pathway can be activated by many stimuli,
specificity comes from the selective activation of MAP3K activation by individual stimulus. Upstream kinases MLKs, ASKs, and
TAK1 are activated mainly by high-fat diet (HFD), oxidative stresses, and cytokines, respectively. Abbreviations: ASK, apoptosis
signal-regulating kinase; JIP, JNK-interacting protein; MLK, mixed lineage kinase; POSH, Plenty of SH3.
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the specificity of these biological responses, which occur in the broad scope of JNK signaling, most likely stems
from the tight upstream and downstream components of JNK signaling. Components included such as scaffolding
proteins bring together a complex of specific JNK signal transducers. Belowwe discuss different scenarios that explain
the coexistence of JNKs many functions and response specificity (Figure 1).
JNK-targeting stimuli trigger the activation of particular upstream kinases, MAP3Ks, includingMLKs (Mixed lin-
eage kinases), TAK1 (Transforming growth factor β-activated kinase 1), ASK (Apoptosis signal-regulating kinase),
and MEKK (Mitogen-Activated Protein Kinase Kinase Kinase). Whereas MAP3K MLKs are mainly responsible for
JNK activation by FFA [8–12], ASK plays a major role in ROS-induced JNK activation [13,14]. TAK1, another mem-
ber of MAP3K family, plays an important role in cytokine-mediated JNK activation [15,16]. Activation of MAP3K
kinases results in further activation of members of the MAP2K family (specifically MKK4 and MKK7) via phospho-
rylation (Figure 1). Both MKK4 and MKK7 activate JNK by phosphorylation on its conserved Thr-Pro-Tyr motif
[3]. However, MKK4 prefers the Tyrosine residue for phosphorylation andMKK7 prefers the Threonine residue [17].
When phosphorylated, JNK modulates a large number of downstream substrates, including but not limited to the
AP1 family of transcription factors (c-Jun, ATF-2, Jun-b, Jun-D, c-myc, NFAT1, NFAT4, Elk-1, MEF-2C, Smad4,
Stat4, TCF, HSF1, DPC4, and p53), [3,7,18,19] (Figure 1).
JNK activity can also be counter-regulated by specific sets of phosphatases, enzymes that remove phosphate groups
from proteins. Specifically, phosphatases MKP1, 2, 5, and 7 have been shown to control JNK activity by dephospho-
rylating JNK [20,21]. The current view holds that the specificity of JNK signaling stems from the ability of its JNK
members to form complexes with different upstream kinases via various scaffold proteins such as the JNK-interacting
proteins (JIP1, JIP2, JIP3, JIP4) [22], the Arrestins (2 and 3) [23–25], and Plenty of SH3 (POSH) [26] (Figure 1).
While there are functional redundancies between Jnk1, 2, and 3, knockouts of a single Jnk member do not have
the same phenotypes as double or triple -Jnk deficient animals. It is therefore appropriate to interpret these data from
single knockout models cautiously, as other members or splice variants may have overlapping functions (Table 1)
[27]. Alternatively, deletion of one JNK or JNK pathway regulator could potentially lead to up-regulation of different
isoforms, making the resultant phenotype difficult to interpret. It is important to note that the alternative splicing of
JNK isoforms have important implications for the interpretation of experimental results in different mouse models.
As recent data show, JNK1 and JNK2 both have active and inactive splice variants, as well as phenotypes of knockout
mice that can arise from the expression of differential splice variants in particular tissues [28]. For simplicity, unless
specified, we will use the term JNK in reference to all three isoforms (JNK1, JNK2, and JNK3) in this review.
JNK links chronic inﬂammation to cardiometabolic diseases
Cardiometabolic diseases are characterized by a heightened inflammatory state, thought to promote disease and asso-
ciated comorbidities [51–56]. JNK kinases have been thoroughly described for their role in cytokine signaling [8,57].
Data have demonstrated that cytokines can activate the JNK signaling pathway, but also that the JNK pathway is
responsible for producing cytokines. The JNK kinases are responsible for sensing multiple stressors and reacting, ul-
timately resulting in proliferation, cell survival, or potentiating cell death if necessary via apoptosis. Under normal
conditions these strategies serve to protect the organism by providing a platform for fast activation of downstream
responses to an inflammatory stressor [8,27]. However, when homeostasis becomes dysregulated JNK activation is
prolonged and results in aberrant apoptosis and chronic inflammation aremediated through prolonged cytokine pro-
duction [30,51–56,58–62]. Therefore, JNK has an important role connecting the inflammatory response to the onset
of multiple metabolic disorders [30,58,59].
Inflammation is a powerful biological response required to remove harmful agents from the body via both innate
and adaptive immune responses. However, when the inflammatory response becomes chronically activated it can
contribute to the onset of chronic diseases such as diabetes, obesity, and atherosclerosis [58,63]. The first evidence
of the link between JNK and cardiometabolic inflammation is demonstrated by the JNK-dependent infiltration of
immune cells (macrophages, T cells etc.) into adipose tissue and liver [63]. These macrophages were shown to be re-
sponsible for producing pro-inflammatory cytokines such as TNFα and IL6, ultimately resulting in impaired insulin
signaling, insulin resistance (Table 1) [58,59,64,65], and cardiovascular diseases [56,66,67]. Under these conditions,
JNK promoted cytokine production via AP1-driven gene transcription [68,69], thus triggering chronic inflamma-
tion. Furthermore, JNK upstream kinases MLKs and TAK1 promote cytokine production and inflammation (Table
1) [16,70]. Together these data indicate that targeting JNK may decrease chronic whole-body inflammation, thus,
decreasing CMS onset and progression.
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Table 1 Mouse models and their outcomes of JNK pathway deﬁciency
Disorder Mouse model Tissue Outcome References
Obesity/IR Jnk1−/− Whole body JNK1-deﬁcient mice were protected from obesity and insulin
resistance
[29,30]
Mlk2−/−Mlk3−/− Whole body The sympathoadrenal system contributes to the increased energy
expenditure in MLK-deﬁcient mice
[8, 9]
Jip1−/− Whole body Jip deﬁciency decreased inhibitory phosphorylation of IRS-1 on
Ser307 and therefore increased insulin sensitivity
[31]
Jnk1−/− Adipocyte Mice with Jnk1-deﬁcient adipocytes exhibit dramatically improved
hepatic insulin sensitivity partially through less IL6 production by
adipocytes
[30,32]
Jnk1−/− Liver Promotes insulin resistance [30,33]
Jnk1−/− Jnk2−/− Liver JNK-mediated inhibition of hepatic FGF21 promotes insulin
resistance
[34]
Jnk1−/− Muscle Reduced muscle LPL expression might contribute to the increased
muscle insulin sensitivity in JNK1-deﬁcient mice
[30,35]
Jnk1−/− Brain Nervous system Jnk1 deﬁciency caused increased expression of
thyrotropin releasing hormone (TRH) in the hypothalamus, thyroid
stimulating hormone (TSH) by the pituitary gland, and increased
circulating levels of thyroid hormones (T3 and T4) in the blood.
Thus hypothalamic–pituitary–thyroid axis is a crucial target of JNK1
that controls obesity
[30,36,37]
Jnk1−/− Jnk2−/− Anterior pituitary gland JNK-diﬁcient mice exhibited an increase in the pituitary expression
of thyroid-stimulating hormone (TSH)
[38]
Jnk3−/− AgRP neuron JNK3 deﬁciency causes hyperphagia selectively in high-fat diet
(HFD)-fed mice
[39]
Jnk1−/− Jnk2−/− Monocytes JNK was necessary for pro-inﬂammatory macrophage (M1)
polarization
[40]
Jnk1−/− Pancreatic b cells JNK1 inhibits glucose-induced insulin production [41]
Atherosclerosis Jnk1−/− Endothelium JNK1 required for apoptosis and atherosclerosis [42]
Jnk1−/− Bone marrow
transplant
JNK1 deﬁciency promotes disease [43]
Jnk2−/− Whole body JNK2 deﬁciency reduced SR-A receptors endocytosis, therefore,
less foam cell formation
[44]
Abdominal aortic
aneurysm
SP600125/Jnk2−/− Whole body JNK2 deﬁciency reduced secretion of MMP-9 and MMP-2 from
VSMCs, THP-1 macrophages
[45]
Myocardial infraction Jnk1−/− Pro-survival role when the period of ischemia is brief and injurious
when the period of ischemia is extended
[46]
Ask1−/− Whole body Protection [47–49]
Peripheral artery
disease (PAD)
Jnk1−/− Jnk2−/− Endothelium JNK deﬁciency promotes PAD [50]
JNK in inﬂammation and insulin resistance
JNK activation following a high-fat diet (HFD) results in inflammation, obesity, and insulin resistance (extensively re-
viewed in Solinas andBecattini [62]), all of which are risk factors for atherosclerosis and cardiovascular disease. JNK is
critical for adipose tissue IL6 production, which is chronically elevated in mice after HFD and leads to impaired hep-
atic insulin signaling via STAT3–SOCS3 axis which leads to insulin receptor substrate 1 (IRS1) degradation [32]. In
addition, JNKs seem to play a significant role in peripheral insulin resistance via cytokine production, inflammation
and disruption of insulin signaling. JNK1 removal from hematopoietic compartments of mouse leads to the protec-
tion against HFD-induced insulin resistance by decreasing obesity-induced inflammation [71] which, by extension,
may decrease risk for other chronic inflammatory diseases such as atherosclerosis.
In addition to increasing cytokine production by myeloid and other immune cells, JNK activation can con-
trol macrophage polarization and T-cell differentiation. [40,72]. Macrophages can be generally classified into two
main categories according to their polarization: M1 (pro-inflammatory) and M2 (anti-inflammatory). The ratio of
macrophage polarization determines the overallmacrophage function and can affect disease conditions [54,55,73,74].
In adipose tissue, JNK is directly involved in controllingmacrophage polarization. Consequently, this results in an in-
crease in the M1 population leading to insulin resistance in mice on HFD [40]. This may also be particularly relevant
in the development of atherosclerosis.
4 © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 2. JNK controls insulin signaling
JNK activation in the liver suppresses Fgf21 production, therefore reducing Fgf21 action on its target tissues, including liver, muscle,
and adipose tissue, thus leading to insulin resistance. JNK activation also attenuates insulin signaling via increased Il6 production
in adipose tissue, which then promotes IRS1 protein degradation in liver.
The liver can play an important role in cholesterol production and recycling as well as insulin signaling and gluco-
neogenesis. In themouse liver, JNK plays a vital role in controlling the PPARa–FGF21 hormone axis which is required
for fatty acid oxidation and ketogenesis [34]. In addition, PPAR has been exploited to treat hyperlipidemia and has
been implicated in cardiovascular diseases in human [75,76]. Data from a recent study have shown that JNK in the
liver tissue of mouse plays a critical role in insulin resistance via suppression of PPAR-controlled FGF21 pathway [34]
(Figure 2).
Airways inflammation is a common phenomenon in chronic obstructive pulmonary disease (COPD). COPD is a
co-morbidity of insulin resistance. A recent study examining insulin resistance of rat model showed thatWnt5a/JNK1
activation promoted macrophage activation and COPD [77].
Furthermore, upstream activators of the JNK pathway have recently been studied for their role in insulin resistance.
Specifically, deficiency of the MAP3K MLKs or of the scaffold protein JIP, promotes insulin sensitivity in HFD-fed
mice [9,31]. Collectively the data from these different studies support that the JNK pathway is required for insulin
resistance mediated by multiple tissues (Figures 1 and 2).
JNK in obesity
Obesity is strongly and independently associatedwith increased cardiovascular risks andmortality. In obesity, chronic
inflammation is observed in the adipose tissue. Specifically, the visceral adipose tissue displays macrophage infiltra-
tion and acts as a secretory organ to introduce cytokines into circulation, potentially linking obesity to cardiovascular
disease. Obesity is also associated with increased plasma FFA which are known to mediate many adverse metabolic
effects leading to insulin resistance and atherosclerosis [78,79]. In cell culture, FFAs activate JNK [9] most likely
through an activation of the upstream kinase, MLK, a member of the MAP3K family [10,12]. MLK is required for
JNK activation in adipose tissue in mice on HFD (Table 1) [9]. Recently a scaffold protein JIP1 was shown to medi-
ate a new pathway of FFA-induced JNK activation. Previously it has been shown that a non-receptor tyrosine kinase
Src is also needed for FFA-induced JNK activation [11]. However, recent papers implicated that JIP1 is required
for FFA-induced Src phosphorylation and its subsequent translocation to the membrane. Additionally, JIP tethers
a Src–Vav–RAC1–MLK complex to FFA-dependent JNK activation [10]. This Src–Vav–RAC1–MLK pathway is re-
quired for obesity inmice as data have shown thatmice with JIP, Vav, andMLKdeficiencywere protected fromobesity
after HFD feeding [9,31,80].
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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In addition, the visceral adiposity and vascular insulin resistance in the visceral adipose tissue arterioles of obese
subjects were associated with increased JNK activation and impaired endothelial nitric oxide synthase (eNOS) ac-
tivation. Pharmacological JNK inhibition (with SP600125), markedly improved insulin-mediated vasodilation and
vascular endothelial function, further suggesting JNK as a potential target in obesity-related vascular diseases [81].
The above studies demonstrate that JNK plays an important role in obesity and insulin resistance [30]. But the
bigger picture becomes more transparent from the conditional JNK1/2 -deficient mice in which selective deletion of
JNK1/2 in neurons abolished the ability to gain weight after HFD feeding compared with the control mice [36]. It
has been proposed that JNK plays an important role in the feedback loop of the T3 hormone to the hypothalamus,
wherein, neural JNK1/2-deficient mice lack this feedback response; thus causing them to use more energy, leading
to weight loss [30,36,38,82]. Although JNK1/2 deficiency in peripheral tissue induced insulin sensitivity, there was
no significant difference in obesity in these mice [30,34,35]. On the other hand, the other family member, JNK3, is
highly expressed in the brain. Unlike JNK1/2, JNK3 deficiency actually accelerates weight gain and obesity in mice
after HFD feeding [39]. JNK3 deficiency was associated with enhanced excitatory signaling by AgRP neurons and
hyperphagia [39]. These studies clearly show that JNK in the central nervous system is important in the regulation of
HFD-induced obesity. Furthermore, these studies also reveal the potential different roles of JNK1/2 versus JNK3 in
regulating CNS-dependent effects on weight gain (Table 1).
A recent study attempted to dissect the role of JNK signaling in this interorgan communication between adipose tis-
sue and vessels. A transgenicmouse expressing a dominant-negative JNK (dnJNK) under the control of a P2 promotor,
enabling adipocyte-specific expression of dnJNK, displayed decreased adipose tissue inflammation and circulating
cytokines, as well as reduced early atherosclerosis staining [83]. Notably, visceral transplantation of dnJNK-expressing
visceral tissue protected high-fat fed mice from inflammation and atherosclerosis. Further, administration of the
adipocyte fatty acid binding protein (A-FABP), abolished the protective effect of dnJNK [83], indicating that the
inflammatory effect of JNK in adipocyte is mediated by FABP. These studies indicate that tissue-specific JNK in-
activation may help to delineate the role of JNK signaling in cardiometabolic diseases. Therefore, more studies are
necessary to elucidate the in vivo relevance of these observations.
JNK in atherosclerosis: complicated biology and divergent
experimental results
Atherosclerosis is a highly complex, multi-step pathophysiological process that ultimately can lead to myocardial in-
farction or stroke. Atherosclerosis often occurs in conjunction with systemic inflammation and metabolic disease
as both diabetes and obesity are known associated atherosclerotic risk factors. Atherosclerosis onset and progression
adapts the following general sequence of events: (1)An initiating stimulus such as vascular injury, hypercholesteremia,
or chronic inflammation results in endothelial dysfunction, activation, and/or apoptosis. This leads to increased ves-
sel wall permeability to lipids and an increase in localized inflammation. Under these conditions, endothelial cells
then become ‘activated’ meaning they express adhesion molecules that recruit monocytes and leukocytes to the area;
(2) Monocytes then transmigrate across the blood vessel wall and differentiate into macrophages. As the vessel is
lipid-laden, themacrophages ingest the low-density lipoproteins (LDLs) which gives them a foamy appearance, hence
the term ‘foam cells’. These foam cells promote lesion progression by increasing localized inflammation and ROS pro-
duction; (iii) T and B lymphocytes are recruited to the plaque and smoothmuscle cells are recruited to the lumen and
begin to proliferate and secrete collagen, elastin, and other extracellular matrix proteins.
While multiple cell types contribute to this complex process, many current lines of evidence implicate JNK 1 and
JNK2 activation in each of these steps (Figure 3). As mentioned previously, JNK1/2 plays an important general role
in inflammation and cytokine production. JNK1/2 is expressed in all of the cell types relevant to the onset and pro-
gression of atherosclerosis: endothelial cells, smooth muscle cells, macrophages, and T cells. Elevated JNK activity
has been implicated in the formation and progression of atherosclerotic lesions [84] making JNK signaling critical to
understand in this disease setting.
Initial in vivo studies using a mouse model of atherosclerosis, the Apo lipoprotein E knockout mouse (ApoE−/−)
[44] in combination with either global Jnk1 deletion of global Jnk2 deletion, demonstrated that JNK2 independently
promoted atherosclerotic lesion formation. The present study validates that JNK2 phosphorylation is essential in the
development of foam cells as JNK2 phosphorylates the scavenger receptor-A (SR-A), which is required for lipid uptake
by macrophages, resulting in the formation of foam cells (Figure 3). Inhibition of lipid uptake in the absence of JNK2
results in less foam cell formation and mitigation of atherosclerosis progression in the Jnk2−/− ApoE−/− mice.
6 © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 3. Role of JNK in atherosclerosis
(A) JNK1 promotes apoptosis in endothelium after chronic inflammation and promotes atherosclerosis. (B) Similar to endothelium,
JNK1 in bone marrow-derived immune cells (including monocytes) also promotes apoptosis after chronic inflammation which leads
to less atherosclerosis in mice. (C) On the other hand, JNK2 knockout mice were protected from atherosclerosis through reduced
number of foam cell formation as internalization of scavenger receptor A and lipid accumulation without phosphorylation of receptor
are severely decreased.
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Another recent study has shown that JNK deficiency in hematopoietic compartment increases the atheroscle-
rotic lesion in Ldlr−/− mice. In the present study macrophages were protected from apoptosis which accelerates the
atherosclerosis in JNK-deficient mice [43].
As mentioned above, disturbance in the monolayer of cells that line the vasculature endothelium represents an
early event preceding overt atherosclerosis. The endothelium can be injured by multiple atherosclerotic risk factors,
such as hypertension, hypercholesterolemia, and environmental factors including cigarette smoke [85,86]. Chronic
inflammation can contribute to endothelial dysfunction which can trigger multiple cardiometabolic diseases [87].
Endothelial dysfunction as demonstrated by inability of the endothelium to relax in response to stimuli and compro-
mised nitric oxide bioavailability [88,89] is linked to insulin resistance, inflammatory activation, and is a significant
predictor of cardiovascular events [90]. Recent studies in humans have demonstrated that JNK activation is associ-
ated with endothelial dysfunction as assessed by flow-mediated dilation (an established measure of endothelial func-
tion) [91]. Both cytokines and ROS activate JNK signaling and cause endothelial dysfunction [92], apoptosis, and
endothelial ‘activation’ which promotes monocyte adhesion in areas susceptible to atherosclerotic plaque formation.
With endothelial health in mind, the importance of JNK1 deletion was investigated in the LDL receptor knockout
(LDLR−/−) model of atherosclerosis [42]. This study observed that loss of JNK1 protected in early atherosclerosis as
it prevented induction of endothelial apoptosis (a characteristic of areas having disturbed flow in hypercholesteremic
conditions) [42,93] (Figure 3).
As JNK plays multiple roles and is expressed widely in the tissues responsible for atherosclerosis, the specificity of
the activation and resultant outcomes of JNK signaling likely involve the stimulus and upstream activators/repressors.
As detailed in Figure 1, multiple upstream kinases and phosphatases function to regulate JNK signaling. One of the
negative regulator of JNK, MAP kinase phosphatase-1 (MKP-1), has been investigated in several different models
of atherosclerosis with mixed results. MKP-1 has been identified to prevent endothelial activation in sites resistant
to atherosclerosis [94] suggesting that deletion would augment disease. However, two different studies demonstrated
thatMKP 1 deletion in ApoEmice protectedmice from atherosclerotic lesions [95,96]. One study demonstrated stro-
mal cell-derived factor-1a (SDF-1a), a factor negatively correlated with atherosclerotic lesion size, was increased in
the serum with MKP-1 deletion [95] while the other study highlighted the decrease in monocyte chemoattractant
protein-1 (MCP-1) and decreased capability of monocyte migration in vitro [96]. By contrast, a more recent study in
LDLR−/−mice identified thatMKP-1 deficiency increased lesion formation through it effects on themacrophage phe-
notype. MKP-1 was required for macrophage polarization from M1 (inflammatory) to M2 (anti-inflammatory). In
atherosclerosis, themacrophageM2 phenotype is inversely correlated with lesion size [97]. Therefore, this study indi-
cates that JNKmay also promote atherosclerosis development by influencingmacrophage polarization (M1/M2 ratio)
as discussed above. However, the specific links between JNK-mediated macrophage polarization and atherosclerosis
remain unstudied. Some discrepancies in these studies may be due to different background of the mice (ApoE vs
Ldlr) studied in these experiments as well as the possibility that JNK may play a different role in different cells and
tissue types (macrophages, T-cells, endothelial cells etc.). Temporal and tissue-specific conditional knockout models
will likely help clarify the specific role(s) of JNK in the complex process of atherosclerosis.
JNK and abdominal aortic aneurysms
One disease that often coexists with atherosclerosis is the development of abdominal aortic aneurysm (AAA). Typi-
cally occurring in smokers andmen over the age of 65, these aneurysms are themost common arterial aneurysms and
can be fatal if not diagnosed. The localized dilation of the abdominal aorta involves vascular smoothmuscle hypertro-
phy and chronic inflammation. JNK has been implicated as a critical molecular target in AAAs as human aneurysm
tissue has shown a high level of phosphorylated (activated) JNK [45]. Pharmacological JNK inhibition in two dif-
ferent mouse models of AAA not only decreased the onset of aneurysms, but also caused regression of pre-existing
aneurysms [45]. Taken together, these data support JNK as a critical player in the role of inflammation-related vas-
cular diseases like atherosclerosis and AAA, indicating Jnk may be a robust therapeutic target for disease prevention.
Cardiac hypertrophy and failure
Cardiac hypertrophy is the enlargement and/or thickening (hypertrophy) of the heart muscle that can occur in re-
sponse to multiple stimuli such as mechanical stress, scarring, inflammation, and neurohumoral stimulation. Tran-
sient increases in heart size occur as an adaptive process. However, pathological stresses induce maladaptive hyper-
trophy associated with fibrosis, inflammation, oxidative stress, and ER stress, ultimately resulting in heart failure,
arrhythmias, and potentially sudden death making it a significant health concern [98]. The JNK kinases have been
implicated in multiple parts of these pathways (Figure 4) involved in cardiomyocyte growth and fibrosis. JNK activa-
8 © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 4. Proposed mechanisms through which JNK signaling promotes divergent hypertrophic phenotypes
(A) Extracellular signals activate separate upstreamMAP3Ks and JNK activators, leading to activation of MAP2KsMKK4 andMKK7.
Depending on localization of MAP2K, mediated by specific scaffolding proteins, JNK phosphorylates anti- or pro-hypertrophic
signaling pathways. (B) JNK can play direct or indirect role in LV hypertrophy and heart failure.
tion increases in the human failing heart [99], and MLK an upstream JNK activator expression becomes elevated in
end-stage heart failure patients [100]. JNKs are thought to be involved in re-programing gene expression that, in part,
results in hypertrophic gene expression through regulation of transcription factors such as NFATs, Stats, Creb, c-jun,
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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c-fos, and Gata4. In addition, in multiple contexts, the JNK family both initiates and propagates chronic inflamma-
tion which promotes and exacerbates pathological cardiac hypertrophy [101]. Further, multiple studies in cultured
neonatal cardiac myocytes (CMs) identified that JNK promoted myocyte growth and the fetal gene expression pat-
tern which marks pathologic hypertrophy [102–104]. Taken together, these correlative studies in human patients and
studies in cultured CMs have raised interest in better understanding the biology of JNK signaling in the process of
LV hypertrophy and failure. As JNK signaling represents a major cellular stress response, numerous investigations
have focused on the role of the JNK pathway signaling in modulating the cardiac response to external stresses such
as pressure overload. In this context, a key downstream target of JNK, transcription factor c-Jun, appears important
for some cardiac hypertrophy responses. For example, c-Jun mediates insulin-like growth factor (IGF)-Akt signaling
which leads to the development of pathologic hypertrophy and heart failure, whereas inhibition of c-Jun signaling
inhibits cardiac hypertrophy [105]. The study by Choukroun et al. (1999) [103] was one of the first to report that ex-
pressing a dominant-negative upstream activator of JNK (SEK-1/MKK4) prevented both JNK activation and cardiac
hypertrophy in response to pressure overload. Further, overexpression of a dnJNK inhibited cardiac hypertrophy a rat
LVpressure overloadmodel, through a FOXO3a-mediatedmechanism [106]. Consistentwith these results, transgenic
mice with cardiac-specific overexpression of an activated form of another upstream JNK-activator,MKK7 (Ser281 and
Thr275 to Asp, called MKK7D) exhibited a specific increase in cardiac tissue JNK1 and JNK2 activity, without activa-
tion of ERKor p38 [107]. These cardiacMKK7Dmice died at approximately 7weeks of agewith concomitant evidence
of congestive heart failure, suggesting that excess JNK1/2 activation promoted this adverse cardiac phenotype. In a
recent study, JIP3 deficiency protected against cardiac hypertrophy with suppression of myocardial inflammation,
oxidative stress, fibrosis accumulation, and ER stress in a mouse model of cardiac hypertrophy. The protective effects
of JIP3 knockout on cardiac hypertrophy appeared linked to the inactivation of the JNK pathway [108]. Collectively,
these findings suggest that chronic activation of JNK enzymatic activity promotes pathologic cardiac hypertrophy in
comparison with inhibition of this signaling which opposes this process.
However, several studies suggest alternative effects of JNK on cardiac hypertrophy and on LV failure. Whole body
JNK1−/− mice exhibited an abnormal response to pressure overload by transverse aortic constriction manifested by
reduced LV systolic function within 3 days after pressure overload, which lasted for several weeks before eventually
normalizing. Further, JNK1 deletion did not affect the overall hypertrophic response, though LVs of JNK1−/− mice
did display early cellular apoptosis. These findings suggest that JNK1 plays a protective role to maintain LV systolic
function in the acute phase after pressure overload [109]. Interestingly, JNK1DNmice, as well as combined JNK1+/−;
JNK2−/− mice developed increased early LV hypertrophy after only 3 days of pressure overload, with increased mor-
tality observed in the JNK1+/−; JNK2−/− mice in the chronic setting, further supporting a protective role of JNK
signaling after pressure overload [110]. These two strains also developed baseline LV hypertrophy with aging, though
in these experiments the investigators did not perform LV functional or hemodynamic studies, making it difficult to
interpret whether the hypertrophy and mortality arose from intrinsic CM process, or rather from potential external
stress such as chronic hypertension. Mechanistic studies did demonstrate, however, that disruption of JNK promoted
increased myocardial NFAT activation as assessed by NFAT-luciferase assay, suggesting that JNK normally opposes
CM pathologic NFAT signaling.
The effects ofCM-specific deletion ofMAP2Ks (MKK7andMKK4) havemore recently been investigated inmodels
of heart failure. Transgenic mice with cardiac-specific overexpression of an MKK7-JNK1 fusion protein (which be-
haves like a constitutively active JNK) had normal ventricular weight at baseline but were resistant to stress-induced
cardiac hypertrophy [111]. Further, MKK7 deletion from the CM promoted increased arrhythmia vulnerability in
hypertrophied hearts [110]. Additionally, in response to surgical pressure overload, mice with CM-specific MKK7
deletion developed severe LV hypertrophy, contractile dysfunction, LV dilation, and fibrosis within 1 week of pres-
sure overload, with corresponding increased myocardial NFAT activation [111]. Similarly, CM-specific deletion of
the other JNK-selective MAP2K, MKK4 produced a similar phenotype, with increased pressure overload-induced
LV hypertrophy by 1 week post-TAC, which progressed to overt systolic and diastolic dysfunction after 5 weeks of
TAC [112]. As with MKK7, CM deletion of MKK4 appeared to promote ventricular arrhythmia in mice, with altered
expression and localization of the gap junction protein connexin 43 [113].
Similar discrepant results have been observed with studies of upstream JNK activators, includingMAP3Ks.Whole
body deletion of the MAP3K MEKK1 had no effect on the hypertrophic response to TAC, but led to worsening
contractile dysfunction, LV dilation, and heart failure as evidenced by increased lung mass and mortality [114]. An-
other upstream JNK activator, CDC42, was identified in seminal studies as one of three myocardial-expressed genes
modulated by the microRNA, miR-133 [115]. CM-specific deletion of CDC42 led to increased TAC-induced LV hy-
pertrophy, reduced myocardial JNK activation, worsened systolic function, increased heart failure phenotype, and
enhanced myocardial NFAT activation [116]. Importantly, crossing these mice with CM-specific MKK7 transgenic
10 © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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mice reduced the LV hypertrophic response, indicating that JNK deficiency likely mediated the consequences of
CDC42 deletion from the CM (Figure 4).
CDC42 binds and induces autoactivation of another MAP3K, MLK3 [117]. MLK3 whole body knockout mice
displayed baseline LVH with normal LV function [100]. In response to TAC, however, the MLK3−/− mice developed
more severe LV systolic and diastolic dysfunction, aswell increased LV end diastolic pressures, indicating heart failure.
By 1-month post-TAC the hearts of MLK3 knockout mice displayed more overt LV systolic dysfunction as well as a
pattern of pathological gene expression. Chemical inhibition of MLK3 kinase activity also blunted JNK activation in
cultured CMs, and induced myocyte hypertrophy, suggesting mechanistic effects of MLK3 specific to the CM.
Finally, though not typically considered a MAP3K, the cGMP-dependent protein kinase I α isoform promotes
myocardial JNK activation after LV pressure overload. Mice with selective mutation in the PKGIα leucine zipper
protein interaction domain developed striking early mortality after LV pressure overload, with increased lung mass
indicating heart failure [118]. Interestingly, activation of MKK4 and of JNK was blunted in LVs of these mice as
early as 2 days post-pressure overload. This increased mortality suggests that these mice suffered from impaired
PKG-mediated MKK4-JNK activation.
Several themes emerge from the above studies. First, though the precise roles of JNK signaling in the LV hyper-
trophic process remain unclear, and are likely highly complex, many of these studies identify a critical role of JNK
pathway signaling in promoting and preserving the LV functional response to stress (particularly to pressure over-
load). The increased lung mass, LV end diastolic pressures, and mortality observed in some of these studies further
support that disruption of JNK signaling promotes features of the heart failure phenotype. A number of these studies
suggest a key role of cardiomyocyte JNK signaling in preserving LV functional response early after pressure over-
load. Second, enhanced myocardial cell apoptosis and increased NFAT activation appear prominent in these models,
suggesting that JNK opposes the pressure overload-induced cellular apoptosis and pathological NFAT activation.
Several possibilities may underlie these apparently conflicting findings on the role of JNK signaling in the hyper-
trophic and cardiac functional response to stress. One explanation could be that different upstream stress signals, by
activation of differentMAP3Ks, target various cellular compartments of JNK, thus lead to regulation of different pools
of JNK substrates. As a specific example, JNK phosphorylation of nuclear NFAT promotes pathological NFAT acti-
vation. However, JNK phosphorylation of NFAT outside of the nucleus prevents its nuclear import and thus inhibits
NFAT-mediated gene expression. It is possible to envision a balance of these opposing mechanisms which could be
altered depending on the specific cellular localization of JNK activation. In line with this, as described in detail in the
introduction, different MAP3Ks and upstream JNK activators can be selectively modulated by separate extracellular
signals (such as ROS and FFAs, for example). Further, though different MAP3Ks and MAP2Ks activate JNK, they
do so in the context of specific scaffolding molecules, which likely have molecular and spatial specificity. In other
words, MAP3K-MAP2K-JNK activation at one specific scaffold may target separate substrates and promote different
responses than the JNK activation arising from a different scaffolding complex. Further experimental work will be
required to test this hypothesis.
Finally, both the pro- and anti-hypertrophic evidence outlined abovemust also be interpretedwithin the limitations
of existing genetic models. For example, in vivo, the JNK pathway provides a highly efficient rapid signaling system
to transmit a broad variety of extracellular stresses into intracellular responses. Therefore, it remains unclear whether
the findings from permanent genetic alteration models allow accurate interpretation of the likely finely tuned and
temporally diverse actions of these kinases in the normal state. Moreover, as described above, permanent genetic
deletionmodels, even if cell-specific, may induce splice variants of JNK, or could induce compensatory up-regulation
of redundant enzymes, further confounding the phenotypic interpretation of thesemodels. Finally, while themajority
of the studies of upstream JNK activators provide correlative evidence of reduced JNK activity, they generally do not
provide evidence that rescue of JNK can reverse the pathologic findings. Thus, the degree to which reduction in
JNK actually mediates the above phenotypes remains unclear. For these reasons, further studies will be required
to address these contradictory findings in new model systems. Using a conditional and temporal knockout of all
three JNK isoforms in the heart could further elucidate JNKs role in cardiac hypertrophy and in the heart failure
process. Finally, both inflammation and metabolic dysfunction within the myocardium have become increasingly
recognized as contributing to cardiac hypertrophy and heart failure. However, the roles of JNKs in the regulation
of cardiac metabolism, modulation of cardiac inflammation and immune cell honing to the myocardium remains
largely unexplored. We therefore suggest that better understanding of JNK effects on the cardiac metabolism and
inflammation will help clarify the complex role of this signaling axis in cardiac hypertrophy and failure (Figures 4
and 5).
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Figure 5. JNK in cardiometabolic diseases
A schematic diagram explains the JNK connects the metabolic diseases to cardiovascular disease.
JNK in ischemic injury
Heart attack or acutemyocardial infarction (AMI) affectsmore than 3millionAmericans each year. AMI occurs when
the blood flow to the heart muscle is cut off usually due to a blockage of the coronary arteries from atherosclerosis
resulting in tissue ischemia. While restoration of blood flow (reperfusion) is necessary for survival, reperfusion itself
causes significant injury and stimulates ROS production and inflammatory signaling. Under these conditions JNK
is generally thought to promote injury in mouse [119]. However, it is also recognized that JNK can be protective if
the period of ischemia is brief [46]. Utilizing a pharmacologic inhibitor, SP600125, JNK activity was necessary for
recovery after brief ischemia reperfusion, but at longer time points conferred a destructive presence. This finding
has demonstrated to specifically require JNK1 as JNK1−/− mice demonstrated greater damage after brief ischemia.
Therefore, JNK could be important for the phenomenon known as ‘ischemic preconditioning’ which describes a brief
period of non-lethal injury or ischemia that can often render the tissue resistant to further injury. In the setting of
myocardial infarction, inflammatory mechanisms are triggered by ischemic or necrotic myocardium, which leads to
ventricular remodeling. If the remodeling is pathologic (involving ventricular dilation and thinning), it can worsen
systolic function and, eventually, cause heart failure. In this context, ASK1-JNK1/2 signaling is thought to promote
pathological cardiac remodeling aftermyocardial infarction.Mice lackingASK1 exhibit reduced activation of JNK1/2,
but not p38, in the infarct border zone [47]. This study suggests that ASK1 acts as a specific activator of JNK1/2
signaling in this particular context [70]. The ASK1-deficient mice had reduced cardiac remodeling, with reduced
fibrosis in the border zone and remotemyocardium, reduced diastolic LV dimension, improved fractional shortening,
and reduced cardiomyocyte apoptosis in the border zone [48,49].
JNK activation has been reported in rat heart during exercise [120]. A recent study of a reperfusion injury model
in rat has shown that scaffold JIP inhibitor, SU3327, does not have the ability to protect the heart from IR injury. Use
of JIP inhibitor SU3327 during IR actually aggravated the cardiac dysfunction via mitochondrial dysfunction [121]
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Another condition impacted by ischemia is peripheral artery disease (PAD). PAD affects more than 200 million
people worldwide [122,123]. PAD occurs due to atherosclerotic occlusions of peripheral arteries, primarily of the
legs and to a lesser extent, the arms [122,123] due to underlying risk factors (as described above). Therefore, JNK
signaling is likely important for multiple steps of disease onset and progression. In the setting of PAD, JNK1 and
JNK2 deficiency specifically in the endothelium resulted in impaired blood flow recovery [50] after induction of
a mouse model of PAD (hind limb ischemia; HLI). The present study found JNK is required for collateral vessels
formation during development which is essential in the initial recovery of HLI. The present study showed that the
Notch-JNK pathway was a prerequisite for proper development of collaterals in the hindlimb and concludes that JNK
plays a critical role in vascular development, which can affect vascular disease outcomes such as PAD. However, the
role of JNK in PAD requires further investigation as the role of JNK in macrophages or other cell types important for
mediating blood flow recovery has not yet been investigated.
Cardiovascular JNK biology in CMS: suggestions for
research directions
In humans, CMS characteristics of chronic inflammation, insulin resistance, and metabolic abnormalities contribute
to atherosclerosis and cardiac hypertrophy. These in turn lead to consequences such as heart failure and myocardial
infarction. The studies discussed in this review establish the JNK signaling pathway as an essential regulator of both
CMS and of its consequent conditions. However, while studies in genetically modifiedmice nearly uniformly support
that JNK signaling promotesCMS itself, the findings in studies of CMS consequences such as atherosclerosis and heart
failure have been less uniform.
We suggest several limitations in the current knowledge which if addressed could provide a more holistic under-
standing of the functions of JNK in CMS-related diseases. First, future studies using mutants of upstream MAP3Ks
and MAP2Ks, will be beneficial from investigating a requirement of JNK for the different phenotype in mouse and
other animal models. For example, while MLK3 deletion correlates with reduced JNK activation as well as a number
of phenotypes of JNK deficiency [100], in many cases the ability of JNK activation to rescue the phenotypes remains
unknown. In addition, MLKs and other JNK activating proteins modulate substrates other than JNK through both
kinase dependent and independent mechanisms. Therefore, clarifying JNK-dependent versus JNK-independent car-
diovascular actions of these molecules should be a scientific goal.
Second, the conflicting findings outlined above must be interpreted within the limitations of existing genetic mod-
els. For example, in vivo, the JNK pathway provides a highly efficient rapid signaling system to transmit a broad
variety of extracellular stresses into intracellular responses. Therefore, it remains unclear whether the findings from
permanent genetic alterationmodels, even if tissue-specific, allow accurate interpretation of the likely fine-tuned and
temporally diverse actions of these kinases in the normal state.Moreover, genetic deletionmodels, even if cell-specific,
may induce splice variants of JNK, or could induce compensatory up-regulation of redundant enzymes, further con-
founding the phenotypic interpretation of these models. Ideally, future studies can measure JNK activation across
multiple time-points and cell types throughout given disease processes such as atherosclerosis or heart failure.
From the potential therapeutic perspective, several questions deserve further investigation. First, does modula-
tion of JNK have more potential benefit for acute events (heart attack, decompensated heart failure), or for chronic
conditions such as obesity, insulin resistance, and chronic inflammation? As a related question, can modulation of
JNK in CMS actually prevent downstream acute disease events? Finally, for CMS phenotypes, is it more efficacious to
target upstream JNK activators like MLKs orMAP2Ks, instead of direct modulation of JNK? These questions remain
unanswered but could be straightforward to test.
Concluding remarks
This review summarizes the role of the JNK family in cardiovascular pathology. JNK signaling has emerged as main
regulator of cytokine production and inflammation during obesity and chronic metabolic stress condition. Modula-
tion of the prolonged activation of the JNK pathwaywill be beneficial during deferentmetabolic diseases like diabetes.
Diabetic patients are four times more likely to develop cardiovascular diseases than its controls. Therefore, it would
be natural to predict that controlling the JNK pathway will be beneficial to this group of patients.
Though previously published data are inconsistent on the role of JNK in animal models of atherosclerosis, we
cannot rule out that JNKplays a different role in different cell types. Therefore, there is a possibility that the phenotype
of JNK deletion in the immune cells differ from the endothelial cells. Future studies would be optimal to clarify this
inconsistency by using conditional or inducible knockout animal models.
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As data suggest, JNK plays a key role in obesity-induced pro-inflammatory macrophage polarization and insulin
resistance development. JNK activity also seems to influence cardiac remodeling after ischemic injury/MI. These var-
ious observations are likely the result of discrete mechanisms stemming from stimuli-specific activation of the fifteen
different upstream MAP3K activators of JNK together with several possible combinations of various scaffold pro-
teins in the signaling complex (Figure 1). As JNK1 and JNK2 have overlapping functions, using tissue-specific mouse
models are needed for a comprehensive understanding of the JNK family members’ role both in cardiovascular dis-
eases and to determine whether there is therapeutic potential in blocking these pathways in models of cardiovascular
pathology (Figure 5).
Recently the role of JNK has been implicated in angiogenesis during development. Nonetheless it appears that JNK
plays a minor role in adult angiogenesis, though it is known that JNK is required for apoptosis during prolonged
stress. Although this is not clear, one can predict that JNK can be required for tumor elimination.
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